Topic

psoriasis

Bar chart from the US Icotyde label of clear or minimal skin with at least a two-grade improvement (IGA 0/1) at week 16 in the ICONIC-ADVANCE trials: 68 percent with icotrokinra (n=311), 50 percent with deucravacitinib (n=307) and 11 percent with placebo (n=156) in the first trial, and 71 percent (n=320), 55 percent (n=322) and 9 percent (n=81) in the second. A side panel adds PASI 90 at week 16, 55 and 58 percent with icotrokinra versus 30 and 34 percent with deucravacitinib; IGA 0/1 at week 24, 74 versus 52 percent and 69 versus 56 percent; and clear skin (IGA 0) at week 16, 37 and 37 percent versus 16 and 18 percent.

Icotyde (icotrokinra) for psoriasis: what the trials and the label show

Icotrokinra (Icotyde) is a once-daily tablet that blocks the IL-23 receptor. What the phase 3 trials, the US label and the labels of other psoriasis pills show.

Oct 26, 2026 · 9 min

Evidence map of treatments for psoriasis in skin folds from a 2021 review: low- to mid-potency topical steroids for short courses (grade C for folds, B for genital psoriasis), topical calcineurin inhibitors for longer use (grade B), vitamin D analogs (grade C), topical PDE-4 inhibitors (grade C) and systemic treatment for severe or resistant disease, with ixekizumab grade B for genital psoriasis. A side panel explains grade B as good-quality patient-oriented evidence that is inconsistent and grade C as consensus, opinion or case studies, and gives 4 weeks as the recommended maximum for topical steroids in folds.

Medical

Inverse psoriasis in skin folds: treatment options and what the evidence shows

Inverse psoriasis forms smooth red plaques in skin folds. What the evidence shows for steroid, nonsteroidal and systemic treatment, and which rashes look alike.

Oct 26, 2026 · 8 min